Eiger Biopharmaceuticals (EIGR) Given a $43.00 Price Target at Wedbush

Wedbush set a $43.00 target price on Eiger Biopharmaceuticals (NASDAQ:EIGR) in a research note published on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other brokerages have also weighed in on EIGR. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research report on Tuesday, February 5th. ValuEngine raised shares of Eiger Biopharmaceuticals from a buy rating to a strong-buy rating in a research report on Monday, February 4th. Robert W. Baird started coverage on shares of Eiger Biopharmaceuticals in a research report on Monday, January 28th. They issued an outperform rating and a $47.00 price target on the stock. Finally, BidaskClub lowered shares of Eiger Biopharmaceuticals from a buy rating to a hold rating in a research report on Monday, February 25th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Eiger Biopharmaceuticals has a consensus rating of Buy and a consensus price target of $31.75.

Shares of EIGR opened at $13.52 on Tuesday. The company has a market cap of $260.40 million, a P/E ratio of -3.54 and a beta of 1.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 10.16 and a current ratio of 10.16. Eiger Biopharmaceuticals has a twelve month low of $8.20 and a twelve month high of $18.00.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.10). Analysts predict that Eiger Biopharmaceuticals will post -2.52 earnings per share for the current year.

In other Eiger Biopharmaceuticals news, Director Thomas John Dietz purchased 5,000 shares of the firm’s stock in a transaction on Thursday, December 20th. The shares were purchased at an average price of $9.98 per share, for a total transaction of $49,900.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $99,800. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.90% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of EIGR. Geode Capital Management LLC boosted its stake in shares of Eiger Biopharmaceuticals by 34.9% in the 4th quarter. Geode Capital Management LLC now owns 104,792 shares of the biotechnology company’s stock valued at $1,064,000 after purchasing an additional 27,136 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Eiger Biopharmaceuticals by 127.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 36,750 shares of the biotechnology company’s stock valued at $373,000 after purchasing an additional 20,625 shares in the last quarter. 683 Capital Management LLC boosted its stake in shares of Eiger Biopharmaceuticals by 155.1% in the 4th quarter. 683 Capital Management LLC now owns 1,610,529 shares of the biotechnology company’s stock valued at $16,363,000 after purchasing an additional 979,296 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Eiger Biopharmaceuticals in the 4th quarter valued at $255,000. Finally, Jane Street Group LLC acquired a new stake in shares of Eiger Biopharmaceuticals in the 4th quarter valued at $114,000. Hedge funds and other institutional investors own 81.57% of the company’s stock.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: What is a back-end load?

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.